title: Ebselen. Antioxidant capacity in renal preservation.
abstract: Ebselen (PZ51) was tested for its ability to inhibit oxidative membrane damage and improve outcome of rabbit kidneys rendered cold ischaemic for 72 hr. In view of the rapid metabolism of ebselen, the antioxidant capacities of its two principal metabolites were first compared with that of the parent drug in an in vitro hepatic microsomal lipid peroxidation system initiated by NADPH/Fe(3+)-ADP. The potent antioxidant activity of ebselen was confirmed but metabolite I (2-glucuronylselenobenzanilide) exhibited no antioxidant potential up to a concentration of 50 microM; metabolite II (4-hydroxy-2-methyl-selenobenzanilide) did inhibit lipid peroxidation but was about 80 times less effective than the parent compound. The storage of rabbit kidneys in hypertonic citrate solution at 0 degrees for 72 hr of cold ischaemia resulted in greatly increased susceptibility to oxidative membrane damage in both the cortex and medulla as determined by the subsequent in vitro formation of two markers of lipid peroxidation (Schiff's bases and thiobarbituric acid-reactive material). Inclusion of ebselen (50 microM) in the flush and storage solution led to a highly significant reduction in these oxidative markers in both regions of the kidney. Intracellular and interstitial oedema was noted in organs subjected to 72 hr cold ischaemia and was reduced by ebselen (50 microM in the flush/storage solution). The rate of post-ischaemic lipid peroxidation was found to correlate well with the extent of oedema in the renal medulla (r = 0.84, P less than 0.001) but no such correlation was found in the cortex. Administration of ebselen (5.5 mg/kg i.v. and 100 microM in the flush/storage solution) did not improve the long-term survival of rabbits following autotransplantation of a single kidney stored for 48 or 72 hr. No protective effect of ebselen could be demonstrated either in terms of graded physiological function or histological outcome.
authors.affiliation: Section of Surgical Research, MRC Clinical Research Centre, Harrow, Middlesex, U.K.
authors.forename: J D
authors.initials: JD
authors.lastname: Gower
authors.forename: N J
authors.initials: NJ
authors.lastname: Lane
authors.forename: J G
authors.initials: JG
authors.lastname: Goddard
authors.forename: S
authors.initials: S
authors.lastname: Manek
authors.forename: I J
authors.initials: IJ
authors.lastname: Ambrose
authors.forename: C J
authors.initials: CJ
authors.lastname: Green
mesh_terms: D000818:Animals; D000975:Antioxidants; D001393:Azoles / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D015925:Cryopreservation; D006085:Graft Survival / Q000187:drug effects; D054833:Isoindoles; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D016030:Kidney Transplantation; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008861:Microsomes / Q000378:metabolism; D009926:Organ Preservation / Q000379:methods*; D016566:Organoselenium Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
chemical_list: D000975:Antioxidants; D001393:Azoles; D054833:Isoindoles; D016566:Organoselenium Compounds; C042986:ebselen